ginsenoside + calcium beta-hydroxy-beta-methylbutyrate

Ginsenoside + calcium beta-hydroxy-beta-methylbutyrate is a combination nutraceutical therapy being investigated by **The Sixth Affiliated Hospital, Sun Yat-sen University**. This combination is specifically designed to target the dual challenges of **sarcopenia** (age-related muscle loss) and **cognitive impairment** in the elderly. Calcium beta-hydroxy-beta-methylbutyrate (CaHMB) is a calcium salt of the leucine metabolite HMB, which acts as an anabolic agent by stimulating the mechanistic target of rapamycin (mTOR) pathway and inhibiting the ubiquitin-proteasome system, thereby promoting muscle protein synthesis and reducing muscle breakdown. Ginsenosides, a class of steroid glycosides derived from the *Panax* genus, are included for their neuroprotective properties; they are thought to improve cognitive function by modulating neurotransmitter levels (such as inhibiting acetylcholinesterase), reducing neuroinflammation, and mitigating oxidative stress. The combination therapy aims to improve both physical and mental health outcomes in geriatric populations.

Other names

Ginsenoside and CaHMB combination